MicroMedicine http://journals.tmkarpinski.com/index.php/mmed <p><strong>ISSN 2449-8947</strong><br><strong><a title="MNiSW points: 8" href="http://www.nauka.gov.pl/g2/oryginal/2016_12/c5c2fcb0c283a9eb3d1081020fd3178c.pdf" target="_blank" rel="noopener">MNiSW points 2016: 8</a></strong><br><strong><a title="ICV: 85.54" href="http://journals.indexcopernicus.com/MicroMedicine,p24783445,3.html" target="_blank" rel="noopener">ICV 2018: 85.54</a></strong></p> en-US mmed@tmkarpinski.lh.pl (Joanna Bródka) mmed@tmkarpinski.lh.pl (Joanna Bródka) Mon, 13 Jan 2020 21:52:17 +0100 OJS http://blogs.law.harvard.edu/tech/rss 60 Using prostatic fluid levels of zinc concentration in non-invasive and highly accurate screening for prostate cancer http://journals.tmkarpinski.com/index.php/mmed/article/view/239 <p>Prostate specific antigen (PSA) does not provide the high reliability and precision that is required for an accurate screening for prostate cancer (PCa).&nbsp; The aim of our study was to search for a simple, rapid, direct, preferably non-invasive, and highly accurate biomarker and procedure for the screening for PCa. For this purpose the level of Zn was prospectively evaluated in expressed prostatic fluid (EPF), obtained from 38 apparently healthy males and from 33, 51, and 24 patients with chronic prostatitis, benign prostatic hyperplasia and PCa, respectively. Measurements were performed using an application of energy dispersive X-ray fluorescent (EDXRF) microanalysis developed by us. It was found that in the EPF of cancerous prostates the level of Zn was significantly lower in comparison with those in the EPF of normal, inflamed, and hyperplastic prostates. It was shown that “Sensitivity”, “Specificity” and “Accuracy” of PCa identification using the Zn level in the EPF samples were all significantly higher than those resulting from of PSA tests in blood serum. It was concluded that the Zn level in EPF, obtained by EDXRF, is a fast, reliable, and non-invasive diagnostic tool that can be successfully used by local, non-urologist physicians at the point-of-care to provide a highly effective PCa screening and as an additional confirmatory test before a prostate gland biopsy.</p> <p><strong>DOI: <a href="http://dx.doi.org/10.5281/zenodo.3606848">http://dx.doi.org/10.5281/zenodo.3606848</a></strong></p> Vladimir Zaichick, Sofia Zaichick ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 http://journals.tmkarpinski.com/index.php/mmed/article/view/239 Mon, 13 Jan 2020 21:52:43 +0100